Athersys Is Poised To Snatch The Holy Grail Of Acute Injury
(WorldNews Health)

Intro In this article, I will explain why I believe that Athersys (ATHX), a regenerative medicine company developing a mass-producible, allogeneic stem cell IV therapy for ischemic stroke, will succeed in its Phase 3 trial. And, even if potential competitors eventually secure FDA approval, I believe that Athersys` therapy offers a superior treatment through multiple powerful mechanisms of action and a liberal treatment time window. Source Stroke Market Stroke is a leading cause of death in the U.S; there are approximately 800,000 strokes and 140,000 deaths per year. This accounted for about 1 in 20 deaths between 2000 and 2015. Worldwide, it is the second largest cause of death. In addition...